Acurx Ready To Expand Pipeline With Anthrax Treatment [Seeking Alpha]
Acurx Pharmaceuticals, Inc. (ACXP)
Company Research
Source: Seeking Alpha
Follow Summary Acurx Pharmaceuticals is undervalued, with promising market potential for its lead antibiotic, ibezapolstat, targeting C. difficile infections, a billion-dollar opportunity. Ibezapolstat's Phase 2 trials showed a 96% cure rate, positioning it as a potential game-changer with no preexisting resistance and minimal microbiome impact. The company's second asset showed activity against drug-resistant anthrax, making it a possible candidate for government funding. Financing remains a critical issue; Acurx seeks non-dilutive funding from government programs like BARDA, Project BioShield, and potential partnerships to support Phase 3 trials. quantic69/iStock via Getty Images Readers familiar with my prior research on Acurx Pharmaceuticals ( NASDAQ: ACXP ) know that I have a generally negative view on the antibiotics subsector of drug development due to many new antibiotics being used as a This article was written by Vision and Value 1.67K Follower s Follo
Show less
Read more
Impact Snapshot
Event Time:
ACXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACXP alerts
High impacting Acurx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ACXP
News
- Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset [Yahoo! Finance]Yahoo! Finance
- Acurx Board of Directors Approves Bitcoin as Treasury Reserve AssetPR Newswire
- Acurx Board of Directors Approves Bitcoin as Treasury Reserve AssetPR Newswire
- Acurx Board of Directors Approves Bitcoin as Treasury Reserve AssetPR Newswire
- Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update [Yahoo! Finance]Yahoo! Finance
ACXP
Earnings
- 11/13/24 - Beat
ACXP
Analyst Actions
- 11/14/24 - HC Wainwright
ACXP
Sec Filings
- 11/13/24 - Form 8-K
- 11/12/24 - Form 10-Q
- ACXP's page on the SEC website